Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Date:11/7/2013

million, respectively, in the same periods in 2012. The increases in 2013 compared to 2012 were due to an increase in revenue earned through the Company's strategic collaboration with Teva, as a result of the clinical development activities associated with the AFFINITY trial that was initiated in August 2012.
  • Total operating expenses for the three and nine months ended September 30, 2013 increased to $20.5 million and $49.6 million, respectively, compared to $14.9 million and $30.1 million, respectively, in the same periods in 2012. The increases in 2013 compared to 2012 were due primarily to increased clinical trial expenses associated with patient enrollment and treatment in the AFFINITY and Borealis-1 trials, increased costs related to the investigator-sponsored trials, increased employee expenses due to an increase in the number of employees to support our clinical development activities and increased toxicology expenses related to apatorsen and OGX-225.  These increases were partially offset by lower manufacturing costs due to the timing of apatorsen manufacturing activities.
  • Net loss for the three and nine months ended September 30, 2013 was $10.1 million, or $0.68 per diluted common share, and $25.2 million, or $1.72 per diluted common share, respectively. Net loss for the three and nine months ended September 30, 2012 was $5.9 million, or $0.40 per diluted common share, and $17.0 million, or $1.29 per diluted common share, respectively. The net loss in the nine months ended September 30, 2013 included a non-cash gain on revaluation of the warrant liability of $2.9 million compared with $2.5 million in the nine months ended September 30, 2012. 
  • The Company had $46.8 million in cash, cash equivalents and short-term investments as of September 30, 2013, compared to $75.4 million as of December 31, 2012.
  • 2013 cash guidance:
  • Net cash requirements are expected to be in the range of $40 - $50 million.

  • '/>"/>
    SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
    3. OncoGenex to Present at Credit Suisse Healthcare Investor Conference
    4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    6. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
    7. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    8. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    9. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    10. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
    11. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
    (Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., the ... alcohol-based hand sanitizer, asks food processors and food handling ... hand sanitizer they’re currently using to Best Sanitizers’ ... is critical to fighting cross-contamination and the spread of ... believes there are key criteria that make a hand ...
    (Date:8/28/2014)... Spin-charge converters are important devices in spintronics, an ... charge of electrons but also on their spin ... transformation of electric into magnetic signals and vice ... Sinova from the Institute of Physics at Johannes ... the UK, Prague, and Japan, has for the ...
    (Date:8/28/2014)... , Aug. 28, 2014  Next month, executives from clinical ... key industry events beginning with Patient-Centered Clinical Trials 2014 ... Boston , September 4-5. Patient recruitment experts ... Aaron Fleishman will share insights on the benefits ... variety of tactics – from media to mobile apps – ...
    Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2
    ... N.J., Nov. 10 Aton Pharma, Inc., ... a recent,survey of ophthalmologists regarding issues in ... dry eye. Aton provides the dry eye ... sustained release prescription insert that helps to ...
    ... - Seventh Study Showing Oncotype DX Frequently Changes Treatment ... Recommendations in Clinical Practice -, ... GHDX ) today announced the publication of results from ... way,physicians treat early-stage breast cancer. The study, published in the,October ...
    ... China, Nov. 10 /Xinhua-PRNewswire/ -- 3SBio Inc. (Nasdaq:,SSRX), ... and marketing biopharmaceutical products primarily in China,today announced ... Food and Drug,Administration (SFDA) for approval of NuLeusin ... carcinoma. If approved, NuLeusin is expected to,be the ...
    Cached Biology Technology:Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 2Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 3Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 4Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye 5Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 2Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 3Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 43SBio Inc. Files for SFDA Approval of NuLeusin 23SBio Inc. Files for SFDA Approval of NuLeusin 33SBio Inc. Files for SFDA Approval of NuLeusin 4
    (Date:8/28/2014)... marine protected areas is needed to protect fish species ... from the Wildlife Conservation Society and other organizations, previous ... largest numbers of species, often at the expense of ... , Many vital ecological functions of ocean ... food for millions of people. This study uncovers ...
    (Date:8/28/2014)... researcher and his collaborators have developed an online analytic ... of re-engineering cells for biomedical investigation. CellNet is a ... aid stem cell engineering. Details of CellNet and its ... back-to-back papers in the journal Cell . , ... for all types of cell-based investigations and can potentially ...
    (Date:8/28/2014)... have identified the developmental on-off switch for Streptomyces ... than two-thirds of the world,s naturally derived antibiotic medicines. ... whether it is possible to manipulate this switch to ... study, appearing August 28 in Cell , found ... cyclic-di-GMP and a larger protein called BldD ultimately controls ...
    Breaking Biology News(10 mins):Study finds marine protected areas inadequate for protecting fish and ocean ecology 2New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
    ... the red flour beetle living happily in the flour sack ... University, and many others throughout the world, this pest of ... studying genetics. The superior status of this beetle, Tribolium ... work of two Kansas State University faculty, Susan Brown, professor ...
    ... League Baseball pitchers indicates that the height of the pitchers ... lead to potential injuries because of stress on the shoulder ... William Raasch, M.D., associate professor of orthopaedic surgery at the ... head team physician for the Milwaukee Brewers. Major League Baseball ...
    ... Mich. Michigan State University scientist Ned Walker is taking ... he believes he can help win the battle to save ... million grant from the National Science Foundation, Walker will lead ... the population dynamics of the parasite that causes the deadly ...
    Cached Biology News:Study finds pitching mound height affects throwing motion, injury risk 2Netting mosquitoes to prevent malaria 2
    ... microplate coating using advanced automated high throughput microplate processing equipment ... can also accommodate virtually any lot size of the following ... 8 and 12 well strips, ... 384 well microplate, ...
    ... first biological reagent that eliminates ... not just by inhibiting growth. ... agent that can be used ... The cytotoxicity of Mynox is ...
    Convenient 10X buffer concentrate used to maximize binding to the solid phase in microwell ELISA. Formulated to provide optimal pH and ionic strength for binding of antibodies and some antigens. Co...
    A trigger solution for Flashlight labeled materials....
    Biology Products: